Immune checkpoint blockade therapy includes antibodies that block cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death-1 receptor (PD-1), programmed cell death-ligand1 (PD-L1) and are widely used in melanoma treatment. The gene discussed is CTLA4; the disease is melanoma.